Centre d'Information et de documentation du CRA Rhône-Alpes
CRA
Informations pratiques
-
Adresse
Centre d'information et de documentation
du CRA Rhône-Alpes
Centre Hospitalier le Vinatier
bât 211
95, Bd Pinel
69678 Bron CedexHoraires
Lundi au Vendredi
9h00-12h00 13h30-16h00Contact
Tél: +33(0)4 37 91 54 65
Mail
Fax: +33(0)4 37 91 54 37
-
Résultat de la recherche
3 recherche sur le mot-clé 'epidemiological studies'
Affiner la recherche Générer le flux rss de la recherche
Partager le résultat de cette recherche Faire une suggestion
Brief Report: Prevalence of Pervasive Developmental Disorder in Brazil: A Pilot Study / Cristiane S. DE PAULA in Journal of Autism and Developmental Disorders, 41-12 (December 2011)
[article]
Titre : Brief Report: Prevalence of Pervasive Developmental Disorder in Brazil: A Pilot Study Type de document : Texte imprimé et/ou numérique Auteurs : Cristiane S. DE PAULA, Auteur ; Sabrina RIBEIRO, Auteur ; Eric FOMBONNE, Auteur ; Marcos TOMANIK MERCADANTE, Auteur Année de publication : 2011 Article en page(s) : p.1738-1742 Langues : Anglais (eng) Mots-clés : Prevalence Pervasive developmental disorders Autism Epidemiological studies South America Index. décimale : PER Périodiques Résumé : This pilot study presents preliminary results concerning the prevalence of Pervasive Developmental Disorder (PDD) in South America. It was a three-phase study conducted in a typical town in Southeast Brazil. Case definition was based in a combination of standardized instruments and clinical evaluations by experts. The prevalence of PDD was 27.2/10,000 (95% CI: 17.6–36.8) and some hypotheses were raised to explain this low frequency. Clinical findings of PDD cases were consistent with previous data, such as, male preponderance, more children diagnosed with PDD-NOS than with autistic disorder, and half of them born from older mothers. Moreover, the study raised concerns about treatment of cases, because identification of PDD had been late and access to services has been very limited. En ligne : http://dx.doi.org/10.1007/s10803-011-1200-6 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=148
in Journal of Autism and Developmental Disorders > 41-12 (December 2011) . - p.1738-1742[article] Brief Report: Prevalence of Pervasive Developmental Disorder in Brazil: A Pilot Study [Texte imprimé et/ou numérique] / Cristiane S. DE PAULA, Auteur ; Sabrina RIBEIRO, Auteur ; Eric FOMBONNE, Auteur ; Marcos TOMANIK MERCADANTE, Auteur . - 2011 . - p.1738-1742.
Langues : Anglais (eng)
in Journal of Autism and Developmental Disorders > 41-12 (December 2011) . - p.1738-1742
Mots-clés : Prevalence Pervasive developmental disorders Autism Epidemiological studies South America Index. décimale : PER Périodiques Résumé : This pilot study presents preliminary results concerning the prevalence of Pervasive Developmental Disorder (PDD) in South America. It was a three-phase study conducted in a typical town in Southeast Brazil. Case definition was based in a combination of standardized instruments and clinical evaluations by experts. The prevalence of PDD was 27.2/10,000 (95% CI: 17.6–36.8) and some hypotheses were raised to explain this low frequency. Clinical findings of PDD cases were consistent with previous data, such as, male preponderance, more children diagnosed with PDD-NOS than with autistic disorder, and half of them born from older mothers. Moreover, the study raised concerns about treatment of cases, because identification of PDD had been late and access to services has been very limited. En ligne : http://dx.doi.org/10.1007/s10803-011-1200-6 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=148 Psychotropic Medication Use among Insured Children with Autism Spectrum Disorder / Jeanne M. MADDEN in Journal of Autism and Developmental Disorders, 47-1 (January 2017)
[article]
Titre : Psychotropic Medication Use among Insured Children with Autism Spectrum Disorder Type de document : Texte imprimé et/ou numérique Auteurs : Jeanne M. MADDEN, Auteur ; Matthew D. LAKOMA, Auteur ; Frances L. LYNCH, Auteur ; Donna RUSINAK, Auteur ; Ashli A. OWEN-SMITH, Auteur ; Karen J. COLEMAN, Auteur ; Virginia P. QUINN, Auteur ; Vincent M. YAU, Auteur ; Yinge X. QIAN, Auteur ; Lisa A. CROEN, Auteur Article en page(s) : p.144-154 Langues : Anglais (eng) Mots-clés : Autism spectrum disorder Medications Antipsychotics Comorbidities Epidemiological studies Index. décimale : PER Périodiques Résumé : This study examined psychotropic medication use among 7901 children aged 1–17 with autism spectrum disorder (ASD) in five health systems, comparing to matched cohorts with no ASD. Nearly half (48.5?%) of children with ASD received psychotropics in the year observed; the most common classes were stimulants, alpha-agonists, or atomoxetine (30.2?%), antipsychotics (20.5?%), and antidepressants (17.8?%). Psychotropic treatment was far more prevalent among children with ASD, as compared to children with no ASD (7.7?% overall), even within strata defined by the presence or absence of other psychiatric diagnoses. The widespread use of psychotropics we observed, particularly given weak evidence supporting the effectiveness of these medications for most children with ASD, highlights challenges in ASD treatment and the need for greater investment in its evaluation. En ligne : http://dx.doi.org/10.1007/s10803-016-2946-7 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=298
in Journal of Autism and Developmental Disorders > 47-1 (January 2017) . - p.144-154[article] Psychotropic Medication Use among Insured Children with Autism Spectrum Disorder [Texte imprimé et/ou numérique] / Jeanne M. MADDEN, Auteur ; Matthew D. LAKOMA, Auteur ; Frances L. LYNCH, Auteur ; Donna RUSINAK, Auteur ; Ashli A. OWEN-SMITH, Auteur ; Karen J. COLEMAN, Auteur ; Virginia P. QUINN, Auteur ; Vincent M. YAU, Auteur ; Yinge X. QIAN, Auteur ; Lisa A. CROEN, Auteur . - p.144-154.
Langues : Anglais (eng)
in Journal of Autism and Developmental Disorders > 47-1 (January 2017) . - p.144-154
Mots-clés : Autism spectrum disorder Medications Antipsychotics Comorbidities Epidemiological studies Index. décimale : PER Périodiques Résumé : This study examined psychotropic medication use among 7901 children aged 1–17 with autism spectrum disorder (ASD) in five health systems, comparing to matched cohorts with no ASD. Nearly half (48.5?%) of children with ASD received psychotropics in the year observed; the most common classes were stimulants, alpha-agonists, or atomoxetine (30.2?%), antipsychotics (20.5?%), and antidepressants (17.8?%). Psychotropic treatment was far more prevalent among children with ASD, as compared to children with no ASD (7.7?% overall), even within strata defined by the presence or absence of other psychiatric diagnoses. The widespread use of psychotropics we observed, particularly given weak evidence supporting the effectiveness of these medications for most children with ASD, highlights challenges in ASD treatment and the need for greater investment in its evaluation. En ligne : http://dx.doi.org/10.1007/s10803-016-2946-7 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=298 Relative immaturity and ADHD: findings from nationwide registers, parent- and self-reports / Linda HALLDNER in Journal of Child Psychology and Psychiatry, 55-8 (August 2014)
[article]
Titre : Relative immaturity and ADHD: findings from nationwide registers, parent- and self-reports Type de document : Texte imprimé et/ou numérique Auteurs : Linda HALLDNER, Auteur ; Annika TILLANDER, Auteur ; Cecilia LUNDHOLM, Auteur ; Marcus BOMAN, Auteur ; Niklas LANGSTROM, Auteur ; Henrik LARSSON, Auteur ; Paul LICHTENSTEIN, Auteur Article en page(s) : p.897-904 Langues : Anglais (eng) Mots-clés : ADHD child development pharmacotherapy epidemiological studies Index. décimale : PER Périodiques Résumé : Background We addressed if immaturity relative to peers reflected in birth month increases the likelihood of ADHD diagnosis and treatment. Methods We linked nationwide Patient and Prescribed Drug Registers and used prospective cohort and nested case–control designs to study 6–69 year-old individuals in Sweden from July 2005 to December 2009 (Cohort 1). Cohort 1 included 56,263 individuals diagnosed with ADHD or ever used prescribed ADHD-specific medication. Complementary population-representative cohorts provided DSM-IV ADHD symptom ratings; parent-reported for 10,760 9-year-old twins born 1995–2000 from the CATSS study (Cohort 2) and self-reported for 6,970 adult twins age 20–47 years born 1959–1970 from the STAGE study (Cohort 3). We calculated odds ratios (OR:s) for ADHD across age for individuals born in November/December compared to January/February (Cohort 1). ADHD symptoms in Cohorts 2 and 3 were studied as a function of calendar birth month. Results ADHD diagnoses and medication treatment were both significantly more common in individuals born in November/December versus January/February; peaking at ages 6 (OR: 1.8; 95% CI: 1.5–2.2) and 7 years (OR: 1.6; 95% CI: 1.3–1.8) in the Patient and Prescribed Drug Registers, respectively. We found no corresponding differences in parent- or self-reported ADHD symptoms by calendar birth month. Conclusion Relative immaturity compared to class mates might contribute to ADHD diagnosis and pharmacotherapy despite absence of parallel findings in reported ADHD symptom loads by relative immaturity. Increased clinical awareness of this phenomenon may be warranted to decrease risk for imprecise diagnostics and treatment. We speculate that flexibility regarding age at school start according to individual maturity could reduce developmentally inappropriate demands on children and improve the precision of ADHD diagnostic practice and pharmacological treatment. En ligne : http://dx.doi.org/10.1111/jcpp.12229 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=237
in Journal of Child Psychology and Psychiatry > 55-8 (August 2014) . - p.897-904[article] Relative immaturity and ADHD: findings from nationwide registers, parent- and self-reports [Texte imprimé et/ou numérique] / Linda HALLDNER, Auteur ; Annika TILLANDER, Auteur ; Cecilia LUNDHOLM, Auteur ; Marcus BOMAN, Auteur ; Niklas LANGSTROM, Auteur ; Henrik LARSSON, Auteur ; Paul LICHTENSTEIN, Auteur . - p.897-904.
Langues : Anglais (eng)
in Journal of Child Psychology and Psychiatry > 55-8 (August 2014) . - p.897-904
Mots-clés : ADHD child development pharmacotherapy epidemiological studies Index. décimale : PER Périodiques Résumé : Background We addressed if immaturity relative to peers reflected in birth month increases the likelihood of ADHD diagnosis and treatment. Methods We linked nationwide Patient and Prescribed Drug Registers and used prospective cohort and nested case–control designs to study 6–69 year-old individuals in Sweden from July 2005 to December 2009 (Cohort 1). Cohort 1 included 56,263 individuals diagnosed with ADHD or ever used prescribed ADHD-specific medication. Complementary population-representative cohorts provided DSM-IV ADHD symptom ratings; parent-reported for 10,760 9-year-old twins born 1995–2000 from the CATSS study (Cohort 2) and self-reported for 6,970 adult twins age 20–47 years born 1959–1970 from the STAGE study (Cohort 3). We calculated odds ratios (OR:s) for ADHD across age for individuals born in November/December compared to January/February (Cohort 1). ADHD symptoms in Cohorts 2 and 3 were studied as a function of calendar birth month. Results ADHD diagnoses and medication treatment were both significantly more common in individuals born in November/December versus January/February; peaking at ages 6 (OR: 1.8; 95% CI: 1.5–2.2) and 7 years (OR: 1.6; 95% CI: 1.3–1.8) in the Patient and Prescribed Drug Registers, respectively. We found no corresponding differences in parent- or self-reported ADHD symptoms by calendar birth month. Conclusion Relative immaturity compared to class mates might contribute to ADHD diagnosis and pharmacotherapy despite absence of parallel findings in reported ADHD symptom loads by relative immaturity. Increased clinical awareness of this phenomenon may be warranted to decrease risk for imprecise diagnostics and treatment. We speculate that flexibility regarding age at school start according to individual maturity could reduce developmentally inappropriate demands on children and improve the precision of ADHD diagnostic practice and pharmacological treatment. En ligne : http://dx.doi.org/10.1111/jcpp.12229 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=237